Fact gives a 10-year forecast from 2023 to 2033.A new analysis by MR on the market for uncommon hemophilia factors. Additional information includes important market-shaping elements like opportunities, restrictions, and drivers. In order to provide information for a clear understanding of important trends, the market is divided into product type, modality, application, end user, and region.
The rising incidence of rare diseases in the global population is a significant problem for the healthcare sector. Hemophilia, one of the rarest bleeding disorders, is typified by a lack of clotting factors in the blood. Patients with hemophilia usually bleed abnormally and for a longer time than healthy people because the hemophilia gene is faulty. Approximately 70% of instances of hemophilia are inherited and usually result from a gene mutation.
ππ¨π°π§π₯π¨ππ π πππ¦π©π₯π ππ¨π©π² π¨π ππ‘π’π¬ πππ©π¨π«π: https://www.factmr.com/connectus/sample?flag=S&rep_id=7801
Patients with hemophilia can live healthy lives if they receive effective treatment. To stop the abnormal bleeding, the patient is injected with the missing clotting factors. The public's increasing awareness of these uncommon illnesses and the government's efforts to prevent and manage them are factors propelling market value expansion. The rapidly expanding worldwide hemophilia patient pool and advancements in hemophilia treatment techniques are expected to drive an increase in the overall demand for rare hemophilia factors throughout the forecast period.
How Can Emerging Companies Enter the Hemophilia Market?
While a minor cut may be of little concern to most, those with hemophilia face serious risks of bleeding and other complications from even the smallest injury. Hemophilia, affecting approximately one in every 5,000 male births, is caused by a genetic mutation that impairs the production of clotting proteins. Though rare, it can also occur in women, often leading to progressive joint damage or recurrent bleeding in affected areas.
Current gene therapies for hemophilia are limited, primarily benefiting individuals without immune system complications following therapy. Moreover, most treatments are aimed at patients with hemophilia A or B who lack inhibitors, leaving a gap in care for those with both forms of the disease and inhibitors. To fill this gap, emerging companies are heavily investing in research and development to bring new therapies to market.
GeneVentiv Therapeutics, a U.S.-based startup, is leading the way with the first universal gene therapy for hemophilia, even in the most challenging cases. This innovative approach brings new hope to hemophilia patients, offering potential solutions for managing the long-term effects of this genetic condition.
Country-Wise Insights
What’s Fueling the Demand for Rare Hemophilia Factors in South Korea?
"Rising Prevalence of Hemophilia in the Country"
The growth of the rare hemophilia factor market in South Korea is driven by therapeutic advancements, increased consumer awareness of advanced products, a rising prevalence of hemophilia, and the presence of a large patient population.
What is the Outlook for Rare Hemophilia Factor Demand in the U.S.?
"Reimbursement Policies Backed by the U.S. Government"
In the U.S., numerous research grants from the National Organization for Rare Disorders (NORD) and new FDA approvals for coagulation factor concentrates have boosted market growth. Additionally, strong healthcare infrastructure, government-supported reimbursement policies, and continuous innovations from leading companies are fueling the market's expansion.
Competitive Landscape
Several leading companies are adopting strategies such as strategic partnerships and targeted marketing to increase awareness of innovative treatments.
For example:
In 2020, Novo Nordisk introduced ESPEROCT, a long-acting recombinant factor VIII therapy, to prevent and treat bleeding in individuals with hemophilia A. This groundbreaking treatment is primarily recommended for routine prophylaxis to reduce major bleeding episodes, offer on-demand treatment, and manage bleeding during surgical procedures.
Comments
0 comment